Short answer
CRISPR Therapeutics AG (CRSP) filed its fiscal 2025 10-K annual report with the SEC on Feb 12, 2026. It reported revenue of $4M (−90.6% year over year) and net income of −$582M.
- Top risk flagged: Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
FY2025 key financial metrics · XBRL
- Revenue
- $4M
- −90.6% YoY
- Net income
- −$582M
- −58.8% YoY
- Operating margin
- -18933.6%
- −17683.3 pp YoY
- EPS (diluted)
- −$6.47
- −49.1% YoY
- ROE
- -30.3%
- −11.3 pp YoY
- Operating cash flow
- −$345M
- −141.7% YoY
Source: XBRL data from the CRISPR Therapeutics AG (CRSP) FY2025 10-K on SEC EDGAR. USD.
CRISPR Therapeutics AG FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Development and commercialization of transformative CRISPR/Cas9 gene-editing therapeutics for serious diseases including hemoglobinopathies, in vivo editing, CAR T therapies, and regenerative medicine
- New emphasis: First approved CRISPR-based therapy CASGEVY launched globally in 2023 for sickle cell disease and beta thalassemia, with ongoing pediatric trial expansions and targeted conditioning research
- Strategic shift: Increased focus on in vivo editing pipeline using proprietary SyNTase technology and LNP delivery to target liver and other tissues, alongside advancing siRNA programs via Sirius partnership
- Quantitative metric: CASGEVY approved in multiple countries, addressing an estimated 60,000 patients; pediatric pivotal studies show 100% efficacy in vaso-occlusive crisis and transfusion independence endpoints
- Noteworthy fact: CASGEVY is the world’s first approved CRISPR-based gene therapy, representing a major milestone and shifting CRISPR Therapeutics from R&D to commercial-stage biopharma firm
Management Discussion & Analysis
- Operating cash flow used $345.0M in 2025 vs $142.8M in 2024, $202.2M increase due to timing of Vertex milestone payments
- Investing cash flow used $31.8M in 2025 vs $280.5M in 2024, improvement driven by marketable debt securities maturities in 2025
- Financing cash flow provided $426.0M in 2025 vs $332.0M in 2024, mainly from $397.3M ATM common shares sale and $27.7M stock option proceeds
- Outlook: Cash sufficient to fund operations 24 months; dependency on equity/debt financing; risks include volatile markets, regulatory approval uncertainties, and commercial execution
Risk Factors
- Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
- Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position
- Operational vulnerability: Dependence on third-party manufacturers and supply chain to establish clinical and commercial product supply capacity
- Competitive risk: Other gene editing firms' ex vivo/in vivo therapies may trigger additional FDA requirements delaying CRISPR Therapeutics’ programs
- Financial risk: Cash $1,975.8M as of Dec 31, 2025 sufficient for 24 months, but substantial capital raises required thereafter, diluting shareholders
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.